ArticleLeukemia2026

Concordance between bone marrow and blood measurable residual disease after first-line novel agent treatment for chronic lymphocytic leukemia: a systematic review and meta-analysis.

Giuseppe Fiorica et al.PubMed ↗Publisher ↗

No numbers read from the abstract.